Cas9 News and Research

RSS

New insights into cardiac defects in Myotonic Dystrophy Type 1

People with Myotonic Dystrophy Type 1 (DM1), the most common adult-onset form of muscular dystrophy, progressively lose muscle mass and strength in their lower legs, hands, neck and face.

29 Oct 2024

Researchers uncover key mechanisms of CRISPR gene editing

CRISPR/Cas9 is a gene editing tool that has revolutionized biomedical research and led to the first FDA-approved CRISPR-based gene therapy.

28 Oct 2024

Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death.

25 Oct 2024

Scientists reveal how miRNAs shape cancer and offer new paths for treatment

Review explores how microRNAs (miRNAs) interact in cancer development, their potential in diagnosis, and innovative therapeutic strategies, including overcoming chemotherapy resistance.

20 Oct 2024

Adenine base editors show potential to correct X-CGD-causing mutations

A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder characterized by high susceptibility to infections.

16 Oct 2024

Harnessing the power of miRNA for cancer diagnosis and treatment

This study is led by Dr. Shiwei Duan (Department of Clinical Medicine, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China). His team analyzed literature on miRNA, summarizing the close relationship between these small molecules and cancer. miRNA is a type of non-coding RNA that does not encode proteins, but can target more than 60% of human protein-coding genes.

15 Oct 2024

When CDK12/13 stalls, healthy prostate cells take a malignant turn

CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.

7 Oct 2024

ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

Université de Montréal gains access to ERS Genomics' CRISPR/Cas9 patents, launching platforms for genome-wide screening and fostering research collaborations.

From ERS Genomics 1 Oct 2024

CRISPR-Cas13 emerges as a game changer in RNA-targeted therapies

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the development of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) systems.

25 Sep 2024

The role of CRISPR-Cas9 in combating mosquito-borne diseases

Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of insecticides, thus further increasing mosquito resistance and exposing the world to an elevated risk of mosquito-borne diseases.

23 Sep 2024

Enhanced TnpB protein offers new possibilities for gene editing

CRISPR-Cas is used broadly in research and medicine to edit, insert, delete or regulate genes in organisms. TnpB is an ancestor of this well-known "gene scissor" but is much smaller and thus easier to transport into cells.

23 Sep 2024

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.

From MaxCyte, Inc. 23 Sep 2024

Research shows brain synchronization between humans and dogs

Study shows interbrain synchronization in humans and dogs during social interactions, highlighting the impact of autism-related gene mutations in dogs.

16 Sep 2024

New discovery offers hope for overcoming CAR-T cell therapy resistance

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.

12 Sep 2024

Researchers uncover why typically normal protein drives prostate cancer

NSD-2 is crucial for AR activity in prostate cancer, promoting tumor growth and offering a potential therapeutic target for advanced prostate cancer treatment.

12 Sep 2024

VitelloTag approach offers new solution for gene editing challenges in egg cells

A new approach for delivering miniature research tools into the interior of egg cells and embryos has been developed at the Marine Biological Laboratory (MBL), resolving a major bottleneck to using the gene-editing tool CRISPR-Cas9 in many research organisms.

11 Sep 2024

Gene therapy shows dramatic vision improvement for rare inherited condition

The vision of people with a rare inherited condition that causes them to lose much of their sight early in childhood was 100 times better after they received gene therapy to address the genetic mutation causing it.

5 Sep 2024

ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement

Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation center, have signed a non-exclusive commercial-use CRISPR license agreement.

From ERS Genomics 5 Sep 2024

Scientists advance type 1 diabetes treatment with cutting-edge stem cell and gene editing technologies

Researchers review significant advancements and ongoing challenges in cell replacement therapies for type 1 diabetes, highlighting innovative approaches in stem cell-derived islets and immune protection strategies.

5 Sep 2024

Promising new strategy to combat fungal infections

A group of Brazilian researchers has found a potential target for novel therapeutic strategies to combat fungal infections – more specifically, those caused by Aspergillus fumigatus. An article reporting the discovery is published in the journal Communications Biology.

5 Sep 2024

Cas9 News and Research

New insights into cardiac defects in Myotonic Dystrophy Type 1

Researchers uncover key mechanisms of CRISPR gene editing

Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

Scientists reveal how miRNAs shape cancer and offer new paths for treatment

Adenine base editors show potential to correct X-CGD-causing mutations

Harnessing the power of miRNA for cancer diagnosis and treatment

When CDK12/13 stalls, healthy prostate cells take a malignant turn

ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

CRISPR-Cas13 emerges as a game changer in RNA-targeted therapies

The role of CRISPR-Cas9 in combating mosquito-borne diseases

Enhanced TnpB protein offers new possibilities for gene editing

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

Research shows brain synchronization between humans and dogs

New discovery offers hope for overcoming CAR-T cell therapy resistance

Researchers uncover why typically normal protein drives prostate cancer

VitelloTag approach offers new solution for gene editing challenges in egg cells

Gene therapy shows dramatic vision improvement for rare inherited condition

ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement

Scientists advance type 1 diabetes treatment with cutting-edge stem cell and gene editing technologies

Promising new strategy to combat fungal infections

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News